Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
ProQR Therapeutics (Nasdaq: PRQR) has enhanced its Scientific Advisory Board (SAB) with the addition of leading experts in inherited retinal disease and RNA therapies. This strategic move aims to support the advancement of ProQR's RNA therapeutics pipeline. CEO Daniel A. de Boer expressed optimism about the diverse perspectives these experts will contribute. The SAB includes notable figures like James Shannon, Mike Cheetham, and Thaddeus Drija, among others, who collectively bring significant experience in the fields of ophthalmology and RNA drug development.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced a $30 million convertible debt financing agreement with Pontifax Medison Debt Financing to enhance financial flexibility and extend its cash runway into 2023. The deal allows Pontifax to convert the debt into equity at $7.88 per share, a 50% premium to the average share price prior to the agreement. This funding is expected to accelerate the company's RNA therapy pipeline for severe genetic diseases. The financing will occur in three tranches, maturing over 54 months with an initial interest-only period of 24 months.
ProQR Therapeutics (Nasdaq: PRQR) will host an Expert Perspectives call on July 20, 2020, at 5:00 PM EDT, focusing on Leber congenital amaurosis 10 (LCA10) and investigational RNA therapy, sepofarsen. The call will showcase new preliminary data from the ongoing InSight Phase 1/2 extension study, particularly concerning second-eye treatment. Aniz Girach, MD, and Ian MacDonald, MD, will present and interpret the data. Sepofarsen, designed to address the p.Cys998X mutation in the CEP290 gene, has shown promising results with significant vision improvements in trials.
ProQR Therapeutics (Nasdaq: PRQR) announced the launch of its Expert Perspectives call series aimed at discussing topics related to its pipeline and platform. The inaugural call is scheduled for June 22, 2020, at 12 PM EDT, focusing on Usher syndrome and retinitis pigmentosa. It will feature discussions between ProQR's CMO, Aniz Girach, and Dr. Robert Koenekoop from McGill University, covering the investigational therapy QR-421a. Future calls will explore other related topics in genetic rare diseases, emphasizing the company's commitment to advancing RNA therapies.
ProQR Therapeutics (Nasdaq: PRQR) announced a virtual presentation of data from its Phase 1/2 trial of sepofarsen, an RNA therapy for Leber congenital amaurosis 10. The presentation will be made available via ARVO on June 15, 2020, following the cancellation of the annual meeting due to COVID-19. Sepofarsen, designated as an orphan drug, aims to address the genetic mutation causing this rare form of blindness. The trial data, presented by Dr. Stephen R. Russell, will highlight the results of a novel treatment that restores normal function of the CEP290 gene.
ProQR Therapeutics N.V. (NASDAQ: PRQR) announced its Annual General Meeting of Shareholders will be held on June 23, 2020, at 15:00 CET via videoconference. Shareholders can access all relevant documents, including the notice and agenda, on ProQR’s website and the SEC’s website. ProQR is focused on developing transformative RNA therapies for severe genetic rare diseases, leveraging its proprietary RNA repair platform technologies since 2012.
ProQR Therapeutics reported promising interim results from the Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa, with plans for dose expansion and escalation. The company expects to provide updated sepofarsen data in H2 2020. As of March 31, 2020, ProQR held €98.1 million in cash, with a net loss of €16.1 million for Q1 2020. Research and development expenditures increased to €12.8 million, reflecting ongoing clinical trials amidst COVID-19 disruptions. ProQR anticipates sufficient funding to support operations into H2 2022.